Clinical Trial Update: Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating sintilimab and chidamide with or without IBI305 in advanced or metastatic pMMR/MSS colorectal cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microsatellite Stable Colorectal Cancer
• Microsatellite-stable Colorectal Cancer

Drugs mentioned

• Chidamide (chidamide)
• IBI305 (bevacizumab biosimilar)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer | Phase 2 | Status: UNKNOWN